Comparing a new injectable medicine to standard treatment for severe asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new investigational biologic medicine called QL2302, which is given as an injection, to see if it works as well as a similar approved medicine (Tezspire) for people with severe asthma. If you qualify, you would receive either QL2302 or Tezspire, and the study will track how well your asthma is controlled and your lung function over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old and weigh at least 40 kg (about 88 pounds).
- You must have had an asthma diagnosis for at least 12 months.
- You must be using a daily high- or medium-dose inhaled corticosteroid (preventive inhaler) and at least one other daily asthma control medicine for at least 3 months.
- Your lung function must be below normal (but not severely low), and you must have had at least one asthma flare-up in the past year.
- You must not smoke currently or have a significant smoking history (10 pack-years or more).
- You must not have other lung diseases, active infections like hepatitis or HIV, or a recent cancer history (within 5 years, except cured).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if tezepelumab can help reduce severe asthma attacks in children ages 5 to 11. It compares the drug to a placebo (a dummy treatment) to see if it is safe and effective.
This study tests a medicine called tezepelumab (an injection) for people with severe asthma who also have a chronic cough. It may help reduce asthma attacks and improve cough symptoms.
This study tests a new medicine called tozorakimab for adults whose asthma is not well controlled despite using their usual inhalers. It aims to see if it can reduce asthma attacks and improve symptoms.
This trial tests an investigational drug called TQC2731 for people with severe asthma that is not well controlled despite high-dose inhaled steroids. The study aims to see if this treatment can reduce asthma attacks.
This study tests an investigational medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with current treatments. The goal is to see if it can reduce asthma attacks and improve breathing.
This trial tests a medication called tezepelumab to see if it can improve symptoms for people with chronic sinusitis and nasal polyps who also have severe asthma. It may help reduce inflammation and improve breathing and nasal symptoms.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.